8. Huntington disease Clinical trials / Disease details
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04201834 (ClinicalTrials.gov) | August 13, 2020 | 13/12/2019 | Risperidone for the Treatment of Huntington's Disease Involuntary Movements | Risperidone for the Treatment of Huntington's Disease Chorea | Huntington Disease;Chorea | Drug: Risperidone;Device: BioStamp nPoint device | University of Rochester | NULL | Suspended | 18 Years | 65 Years | All | 12 | Phase 2 | United States |
| 2 | NCT04071639 (ClinicalTrials.gov) | March 12, 2020 | 26/8/2019 | Symptomatic Therapy for Patients With Huntington's Disease | Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients | Huntington Disease | Drug: Haloperidol 2Mg Tab;Drug: Risperidone 1Mg Tab;Drug: Zoloft 50Mg Tablet;Drug: Idebenone;Drug: Deutetrabenazine Oral Tablet [Austedo] | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Recruiting | N/A | N/A | All | 60 | Phase 1 | China |